AETHLON MEDICAL INC
AEMDNASDAQTrading Snapshot
- Day Range
- $6.20 – $6.34
- 52-Week Range
- $1.41 – $41.50
- Volume
- $2.98B
- Avg Volume
- $2.86B
- Shares Outstanding
- 526,711
- Next Earnings
- Nov 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $279,201
- Last Q Revenue
- $66,706
- P/E Ratio
- -0.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-18.03
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −53.3%
Why Investors Own AEMD
- ✓High-growth profile — revenue up -4.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AETHLON MEDICAL INC
AEMD
StockOtter · stockotter.spaceAbout AETHLON MEDICAL INC
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)PR NewswireNEW YORK, Sept. 18, 2026NEW YORK, Sept
Aethlon Stock Pulls Back: What's Going On?
Aethlon Medical Inc. (NASDAQ:AEMD) shares are dropping Friday, pulling back after the stock surged more than 300% the previous day.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruger & Company, Inc. (NYSE – RGR), Atkore, Inc. (NYSE – ATKR), Centerspace (NYSE – CSR), Aethlon Medical, Inc. (Nasdaq – AEMD)
BALA CYNWYD, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmit
Aethlon Medical Pivots to Biotechnology with All-Stock Merger
Aethlon Medical Inc. (NASDAQ:AEMD) stock on Thursday skyrocketed after the company signed an all-stock merger agreement with privately held biotech firm North Immunology Inc.
AEMD Stock Alert: Halper Sadeh LLC is Investigating Whether Aethlon Medical, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Aethlon Medical, Inc. (NASDAQ: AEMD) and North Immunology, Inc. Upon closing of the proposed transaction, Aethlon s
Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
North Immunology's lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and non-type 2 inflammation, with the potential to deliver a best-in-disease treatm